OptimizeRx Corp. (OPRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$7.87-1.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · OPRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Reiterate full-year 2026 revenue guidance of $95 million to $100 million despite some year-over-year revenue decline and customer concentration risks.
Stated as a priority in 2 of last 2 quarters. Revenue declined 30% year-over-year from $29.2 million in 2025-Q2 to $20.5 million in 2026-Q2. Despite this decline, management reiterated full-year 2026 revenue guidance of $95 million to $100 million, reflecting confidence in customer investment and commercial momentum. The trajectory shows management maintaining growth targets amid near-term revenue pressure.
“We reiterate full-year 2026 guidance of $95 million to $100 million in revenue.”
“The Company is updating its fiscal year 2026 guidance, and now expects revenue of $95 million to $100 million.”
Maintain adjusted EBITDA guidance of $21 million to $25 million for fiscal year 2026 with focus on margin expansion and disciplined execution.
Stated as a priority in 2 of last 2 quarters. Adjusted EBITDA was $4.9 million in 2026-Q2, down from $5.8 million in 2025-Q2, reflecting margin contraction. Management reiterated full-year 2026 adjusted EBITDA guidance of $21 million to $25 million, emphasizing disciplined execution and margin expansion. The trajectory shows management maintaining cost discipline despite near-term EBITDA pressure.
“We reiterate full-year 2026 guidance of $21 million to $25 million in adjusted EBITDA.”
“Adjusted EBITDA guidance unchanged at $21 million to $25 million.”
Continue debt refinancing and principal repayments to improve financial position and reduce interest expense.
Stated as a priority in 2 of last 2 quarters. Management paid down $5.3 million of term loan principal in 2026-Q2, ahead of schedule, and an additional $3.0 million after quarter-end. Long-term debt declined from $21.4 million at 2025-Q4 to $17.8 million at 2026-Q2. The trajectory shows delivering on balance sheet strengthening and debt reduction commitments.
“Paid down $5.3 million of term loan principal during the quarter—$5.0 million ahead of schedule.”
“Paid off $2.7 million of principal and exited the first quarter of 2026 with $23.6 million in debt.”
Invest in AI-enabled audience intelligence, programmatic point-of-care activation, and clinical workflow engagement to drive recurring growth.
Stated as a priority in 2 of last 2 quarters. Management highlighted ongoing investments in AI-driven platform capabilities and programmatic initiatives to enhance customer engagement. While no direct financial metrics quantify this progress yet, the recurring focus indicates sustained strategic emphasis on product innovation.
“Continued investment in platform capabilities, including recent product launches and expanded programmatic initiatives.”
“Expanding our platform capabilities by opening our proprietary electronic health record network to demand-side platforms (DSPs).”
Appoint experienced independent directors to enhance strategic oversight and support company transformation.
Newly stated in 2026-Q2. Management appointed Mary Varghese Presti to the Board to support growth and operational rigor. This is a strategic talent priority with no direct financial metrics yet but signals focus on strengthening governance and expertise.
“Appointment of Mary Varghese Presti to Board to help accelerate growth and expand product portfolio.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Over the trailing year it converted 0.05x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.